Section III Trial Reveals Lilly’s Tirzepatide is Superior to Rival in Kind 2 Diabetes


Jonathan Weiss / Shutterstock

Eli Lillys The Phase III SURPASS 2 clinical trial shows treatment with tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonists, compared to superior body weight reductions and of blood sugar is associated with injectable semaglutide in adults with type 2 diabetes.

Diabetes affects approximately 34 million people in the United States and up to 463 million adults around the world. Semaglutide, a GLP-1 receptor agonist approved in 2017 as an add-on treatment to diet and exercise that increases insulin secretion in patients with type 2 diabetes. While this is effective, it hasn’t stopped other drug companies from looking for more effective options to treat this metabolic disorder.

Lilly’s Tirzepatid has been suggested as a potentially effective treatment option that rivals the effectiveness of semaglutide.

in the February, the Company shown This tirzepatide significantly reduced A1C, a marker of blood sugar, and body weight in adults with type 2 diabetes, as shown in the 52-week Phase III SURPASS-3 and SURPASS-5 studies. Both studies found a 2.37% and 2.59% reduction in A1C and a 13.9% and 11.6% reduction in body weight.

Recently announced The topline results of the 40-week SURPASS-2 study show that the highest dose of tirzepatide of 15 mg was associated with an A1C reduction of 2.46% and a body weight reduction of 13.1%. Even the lowest dose of tirzepatide at 5 mg reduced A1C significantly by 2.09% and body weight by 8.5% compared to semaglutide with 1.86% and 6.7%, respectively.

Approximately 51% of the patients in the study who took the higher dose of tirzepatide achieved an A1C of less than 5.7%, a value seen predominantly in people without diabetes compared to 20% in the semaglutide arm. Overall, the safety profile of tirzepatide was similar to the other SURPASS studies, with the most commonly reported adverse events being gastrointestinal.

“Head-to-head studies are the gold standard for clinicians evaluating the effectiveness of trial treatments. These results show that all three doses of tirzepatide were superior to A1C and higher than the highest approved dose of semaglutide for the treatment of type 2 diabetes Provided weight reductions. “According to a statement by Dr. Juan Pablo Frías, Principal Investigator of SURPASS-2 and Medical Director at the National Research Institute. “Newer treatment options can help people with type 2 diabetes achieve their A1C and weight loss goals. In SURPASS-2, tirzepatide delivered clinically meaningful efficacy beyond what an existing drug in the established class of GLP-1 could achieve Receptor agonist has been observed. “

“Almost nine in ten people with type 2 diabetes in the US are overweight or obese. We strive to provide solutions that not only result in significant A1C reductions but also significant weight loss to meet their needs meet, “added Mike Mason. President of Lilly Diabetes. “These remarkable head-to-head results exceeded our expectations and supported our belief in the value of all three doses of tirzepatide as potential new treatment options for people with type 2 diabetes.”

While Lilly’s SURPASS program found tirzepatide to be superior to semaglutide, it hasn’t stopped Novo Nordisk from the development of semaglutide as Anti-obesity drug, based on current data released in the New England Journal of Medicine. Over the course of the 68-week study, treatment with semaglutide was associated with significant weight loss in people with a body mass index of 30 or higher who did not have diabetes.

Based on these findings, Novo Nordisk has applied for a priority review voucher for a new drug application filed with the US Food and Drug Administration in December.